Analysts Set Fate Therapeutics, Inc. (NASDAQ:FATE) Target Price at $95.00

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) have earned an average rating of “Buy” from the twelve research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have assigned a buy recommendation to the […]

Related Keywords

Alexander Rives ,Leonard Zon ,Scott Wolchko ,Rudolf Jaenisch ,Philip Beachy ,John Mendlein ,Thomson Reuter ,Michael Rudnicki ,Cindy Tahl ,David Scadden ,Morgan Stanley ,Securities Exchange Commission ,Nasdaq ,Fate Therapeutics Inc ,Advisor Group ,Asset Management Americas Corp ,Cantor Fitzgerald ,Sumitomo Mitsui Trust Holdings Inc ,Fate Therapeutics ,Get Rating ,Director John Mendlein ,Exchange Commission ,General Counsel Cindy Tahl ,Management Americas ,Mitsui Trust Holdings ,Sheng Ding ,Nasdaq Fate ,Fate ,Medical ,Ratings ,Consensus ,